EUCTR2016-001278-13-FI进行中（未招募）1 期
Immunologic, genetic and microbiomic predictors of the treatment response for TNFalpha-blocking drugs – prospective follow-up cohort of patients with Crohn’s disease or ulcerative colitis - PROSIBD
Taina Sipponen0 个研究点目标入组 100 人开始时间: 2016年4月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adult patients (18-64 years of age) with active ulcerative colitis and Crohn's disease not resonsive or intolerant to conventional steroid or immunosuppressive medication
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •usual exclusion criteria to TNFalpha-blocking agents: active infection, cancer, severe heart insufficiency, tuberculosis, MS-disease. Indication to infliximab is other than active IBD.
研究者
相似试验
招募中
不适用
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)Coronavirus Disease 19 (COVID-19)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecifiedDRKS00022871CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover400
已完成
不适用
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-PROGRESS)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecifiedDRKS00023277Charité – Universitätsmedizin Berlin, Med. Klinik m. S. Infektiologie und Pneumologie, und Arbeitsbereich Pulmonale Inflammation94
招募中
不适用
Predictive biomarkers and the role of the microbiome determining response to antiinflammatory treatment in Inflammatory Bowel Disease (Crohn's disease and ulcerative colitis)inflammatory Bowel Disease10017969Crohn's diseaseulcerative colitisNL-OMON50413Academisch Medisch Centrum2,240
尚未招募
不适用
Analysis for the prediction of systemic therapies in patients with locally advanced hepatocellular carcinomaNeoplasmsKCT0004206Seoul National University Hospital400
招募中
不适用
Exploratory analysis of biomarkers predicting the treatment response and the prognosis in patients with gastric carcinomaGastric cancerJPRN-UMIN000036886Sapporo Medical University350